Dominick Latrémouille-Viau
Montreal
Education
M.Sc., economics, University of Quebec at Montreal, B.S., economics, University of Quebec at Montreal
Summary of Experience
Ms. Latrémouille-Viau specializes in health care economics and outcomes research. She has extensive experience assessing patient chart review and analyzing the efficacy and economic outcomes associated with a range of pharmaceuticals, medical devices, and interventions using US administrative claims data. Ms. Latrémouille-Viau has worked with large health care firms to conduct studies investigating treatment patterns, comorbidity profiles, safety, resource utilization, direct medical costs, and indirect productivity costs. Her research has covered a variety of diseases, including attention deficit hyperactivity disorder, autoimmune disease, breast cancer, chronic gout, chronic lymphocytic leukemia, chronic myeloid leukemia, and respiratory diseases. Ms. Latrémouille-Viau has published a number of studies in peer-reviewed journals.
Selected Publishing
-
CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Kota V, Maegawa R, Latremouille-Viau D, Jadhav K, Rossi C, Guérin A, Lorga S
-
Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
Journal of Health Economics and Outcomes Research, 2022
2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P
-
Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective
Journal of Health Economics and Outcomes Research, 2022
2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A
-
Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
Journal of Medical Economics, 2021
2021Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X
-
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States
Journal of Managed Care & Specialty Pharmacy, 2021
2021Blaiss MS, Meadows JA, Yu S, Robison DR, Hass SL, Norrett KE, Guerin A, Latremouille-Viau D, Tilles SA
-
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
Leukemia & Lymphoma, 2021
2021Atallah EL, Sadek I, Maegawa R, Cao X, Latrémouille-Viau D, Pivneva I, Rossi C, Guérin A, Kota V
-
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers
Journal of Medical Economics, 2020
2020Shah NR, Bhor M, Latremouille-Viau D, Sharma VK, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Singh MK, Serra E, Davidson M, Xu L, Guerin A
-
Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
Rheumatology and Therapy, January 5, 2019
2019Sunkureddi P, Latrémouille-Viau D, Meiselbach MK, Xie J, Hur P, Joshi R
-
Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review
Drugs - Real World Outcomes, January 7, 2019
2019Joshi R, Latrémouille-Viau D, Meiselbach MK, Xie J, Park Y, Sunkureddi P
-
Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective
Leukemia & Lymphoma, 2019
2019Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL
-
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
Journal of Medical Economics. 2018 Jun;21(6):556-563
2018Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ
-
Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States
Advances in Therapy, 2018 Oct;35(10):1671-1685
2018Seiter K, Latrémouille-Viau D, Guérin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ
-
The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States
Journal of Medical Economics. Jan 2017;20(1):54-62
2017Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.
-
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States
Journal of Medical Economics. Jan 2017;20(1):63-71
2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.
-
Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency
Journal of Managed Care and Specialty Pharmacy. 2017;23(2):214-224
2017Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ
-
The economic burden of common adverse events associated with metastatic colorectal cancer treatment (1)
Journal of Medical Economics. Jan 2017;20(1):54-62
2017Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C
-
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia(1)
Journal of Medical Economics. Jan 2017;20(1):63-71
2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L
-
Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-lin
Current Medical Research and Opinion, 2016 32(5): 817-827. e-pub ahead of print 2016/01/09
2016Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L.
-
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study
Lung Cancer. 2014 Dec;86(3):350-7
2014Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S
-
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis
J Med Econ. 2014 Sep;17(9):646-57
2014Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ
-
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
Pediatr Pulmonol. 2012 Jan;47(1):44-52. doi: 10.1002/ppul.21521. Epub 2011 Aug 3.
2012Sawicki G, Signorovitch J, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L
-
Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis
Am J Med. 2010 Apr;123(4):350-7
2010Kimball A, Guerin A, Latremouille-Viau D, Yu A, Gupta S, Bao Y, Mulani P
-
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis
Dermatology. 2010;220(2):128-37. Epub 2010 Feb 3
2010Saurat J, Guerin A, Yu A, Latremouille-Viau D, Wu E, Gupta S, Bao Y, Mulani P
-
Risk of Hepatotoxicity-Related Hospitalizations Among Patients Treated With Opioid-Acetaminophen Combination Prescription Pain Medications
Pain Med. 2010 Nov;11(11):1718-25
2010Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Viau-Latremouille D, Stangle B, Lafeuille M, Greenberg P
-
Generic antiepileptic drugs and associated medical resource utilization in the United States
Neurology 2010 74: 1566-1574
2010Labiner D, Paradis P, Manjunath R, Duh MS, Lafeuille M, Latremouille-Viau D, Lefebvre P, Helmers S
-
Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension
Curr Med Res Opin. 2010 Apr; 26(4):849-60
2010Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH
-
The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurology
2009Duh M, Paradis P, Latremouille-Viau D, Greenberg P
-
The impact of drug vintage on patient survival: a patient-level analysis using Quebec’s provincial health plan data
Value in Health 2009; Mar 10 [Epub ahead of print]
2009Lichtenberg F, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P
-
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries
Curr Med Res Opin. 2009; 25(7):1793-1805
2009Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille M, Lefebvre P, Gaudig M, Duh MS
-
Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis
Clin J Am Soc Nephrol. 2009; 4(4):755-762
2009Parfrey P, Lauve M, Latremouille-Viau D, Lefebvre P
-
Economic Impact of Generic Substitution of Lamotrigine: Projected Costs in the United States Using Findings in a Canadian Setting
Current Medical Research and Opinion 2008 Apr;24(4):1069-81
2008LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O